Cardiovascular disease Trials in Cambridge, Canada
Conditions / Cardiovascular disease / Cambridge, Canada
Cardiovascular disease has been the subject of sustained clinical investigation across multiple research sites.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01975376 | The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects | TERMINATED | PHASE3 |
| NCT05669755 | REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07000123 | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01594333 | Cardiovascular Inflammation Reduction Trial | COMPLETED | PHASE3 |
| NCT00549757 | Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) | TERMINATED | PHASE3 |
| NCT01394952 | Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) | COMPLETED | PHASE3 |
| NCT07000357 | A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event | RECRUITING | — |
| NCT01975389 | The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects | TERMINATED | PHASE3 |
| NCT00358215 | RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial | COMPLETED | PHASE3 |
| NCT02019264 | A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | COMPLETED | PHASE4 |